News Agency
Men's Weekly

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

  • Written by PR Newswire
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive  Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology,...

Read more: BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical...

Aligning Social, Email, and Web Campaigns with Structured Content: Building a Unified Marketing Engine

Few modern marketing campaigns exist in a bubble. A product launch, for example, may kick off with social media buzz, continue into a targeted email campaign, and finish with a conversion-focused web experience. Ideally, all three touchpoints communicate the same... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion